CognitionTACTIKNCT07771790
Targeted Assessment of Cognition and Tactical-performance With Ingested Ketones
A study testing KetoneIQ® in people with Cognition, run by Florida State University at 1 site in United States.
Trial summary
The goal of this study is to determine whether consuming a commercially available exogenous ketone supplement (KetoneIQ®) affects cognition, specifically marksmanship, under physical stress (i.e., exhaustive exercise). Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Cognition
- What is being tested?
- KetoneIQ®
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 20 participants
- Where
- 1 siteUnited States
- Study dates
- 10 Oct 2026to 31 May 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Active Member of an accredited Law Enforcement Special Weapons and Tactics Team (SWAT)
- Health and capable of meeting testing requirements
Who cannot join
- Following a low-carbohydrate ketogenic diet
- Self-reported Pregnancy
- Allergy to testing materials
- Currently using exogenous ketone supplements within one week of testing
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Institute of Sports Sciences and Medicine
Tallahassee, Florida, 32306
Michael J Ormsbee, PhD, 850-644-2194, mormsbee@fsu.edu
Michael J Ormsbee, PhD
About this study
The goal of this study is to determine whether consuming a commercially available exogenous ketone supplement (KetoneIQ®) affects cognition, specifically marksmanship, under physical stress (i.e., exhaustive exercise).
The main questions we seek to answer are:
- Does the supplement save cognitive performance under stress compared to a placebo?
- Does the supplement improve marksmanship under stress compared to a placebo?
Read the detailed description
In this study, 20 active SWAT team members will be randomized into two groups: Exogenous Ketone Supplement (EKS) and Placebo (PLA).
Participants will complete the trial in a crossover manner (meaning each participant will complete both EKS and PLA conditions)
Our primary outcome of interest is changes in cognitive performance following an exhaustive exercise bout. Secondary outcomes include: changes in marksmanship accuracy and speed, and changes in select biomarkers (catecholamines, cortisol, and BDNF).
Although ketone supplements are marketed for energy and cognitive performance, little is known about how they affect biological markers during stressful environments. Findings from this study may help inform safe, evidence-based use of such supplements among tactical athletes.
- Conditions
- Cognition
- Being tested
- KetoneIQ®, Placebo
- Keywords
- Exogenous Ketones, Cognition, Tactical Athlete
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
KetoneIQ®Dietary supplement
Acute dosage at 0.6g/kg of bodyweight, split into 2 boluses of 0.4 and 0.2g/kg seperated by 45 mins
PlaceboDietary supplement
Taste, texture, and color matched very low calorie placebo
| Study group | Role | What they receive |
|---|---|---|
| KetoneIQ® | Experimental | Supplement of study. KetoneIQ® dosed at 0.6g/kg body weight Receives: Dietary Supplement: KetoneIQ® |
| Placebo | Placebo comparator | Flavor, texture, color matched. Very low calorie. Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cognitive Performance
Changes in Score for the Trail Making Test, Psychomotor Vigilance Test, and Flanker Test.
Measured: Baseline (minute 0) to Post Suppelementation (minute 45) to Post Exercise (minute 60)
Secondary outcomes (5)
Changes in Circulating Concentration of Brain Derieved Neurotrophic Factor
To assess changes in BDNF from baseline to post supplementation to post exercise
Measured: Baseline (minute 0) to post supplementation (minute 45) to post exercise (minute 60)
Changes in Circulating Catecholamines Concetrations
To assess changes in the circulating concentration of epinephrine, norepinephrine, and dopamine
Measured: From baseline (minute 0) to post supplemenation (minute 45) to post exercise (minute 60)
Changes in Circulating Cortisol Concentration
To assess changes in circulating cortisol between groups
Measured: From baseline (minute 0) to post supplemetation (minute 45) to post exercise (minute 60)
Weapons Familarization Score
To assess whether potentially improved cognitive performance translates to tactical-specific tasks. Rifle disassembly, reassembly, and functions check. This will be quantified by number of errors and time to completion
Measured: Post Exercise (minute 60)
Marksmanship efficiency
To determine whether potentially improved cognitive performance translates to live-round marksmanship. Using HIT Factor scoring (an aggregate of accuracy and time to completion, where a higher number is better), we will assess both accuracy and speed to completion for a shuttle fire drill
Measured: Post Exercise (minute 60)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Aug 2026
- Study start10 Oct 2026
- Primary completion31 May 2027 (estimated)
- Study completion31 May 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CognitionStudies of the same condition, open and under way.
- More trials run by Florida State UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Florida State University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Michael J. Ormsbee, Florida State University
- Investigators
- Michael J Ormsbee, PhD, Principal investigator, Florida State University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07771790
- Sponsor's protocol ID
- STUDY00007647: TACTIK
- Other IDs
- FP00009695
- Acronym
- TACTIK
- Status last verified
- Oct 2026
- First submitted
- 10 Aug 2026
- Last updated
- 2 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 2 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Targeted Assessment of Cognition and Tactical-performance With Ingested Ketones
- ClinicalTrials.gov ID
- NCT07771790
- Acronym / sponsor ID
- TACTIK / STUDY00007647: TACTIK
- Conditions
- Cognition
- Keywords
- Exogenous Ketones, Cognition, Tactical Athlete
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Florida State UniversityUniversity, hospital or other
- Study start
- 10 Oct 2026 (actual)
- Primary completion
- 31 May 2027 (estimated)
- Study completion
- 31 May 2027 (estimated)
- First posted
- 18 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this study is to determine whether consuming a commercially available exogenous ketone supplement (KetoneIQ®) affects cognition, specifically marksmanship, under physical stress (i.e., exhaustive exercise).
The main questions we seek to answer are:
- Does the supplement save cognitive performance under stress compared to a placebo?
- Does the supplement improve marksmanship under stress compared to a placebo?
Detailed description
In this study, 20 active SWAT team members will be randomized into two groups: Exogenous Ketone Supplement (EKS) and Placebo (PLA).
Participants will complete the trial in a crossover manner (meaning each participant will complete both EKS and PLA conditions)
Our primary outcome of interest is changes in cognitive performance following an exhaustive exercise bout. Secondary outcomes include: changes in marksmanship accuracy and speed, and changes in select biomarkers (catecholamines, cortisol, and BDNF).
Although ketone supplements are marketed for energy and cognitive performance, little is known about how they affect biological markers during stressful environments. Findings from this study may help inform safe, evidence-based use of such supplements among tactical athletes.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| KetoneIQ® | Experimental | Dietary Supplement: KetoneIQ®Supplement of study. KetoneIQ® dosed at 0.6g/kg body weight |
| Placebo | Placebo comparator | Dietary Supplement: PlaceboFlavor, texture, color matched. Very low calorie. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Active Member of an accredited Law Enforcement Special Weapons and Tactics Team (SWAT)
- Health and capable of meeting testing requirements
Key exclusion criteria (4 listed)
- Following a low-carbohydrate ketogenic diet
- Self-reported Pregnancy
- Allergy to testing materials
- Currently using exogenous ketone supplements within one week of testing
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| KetoneIQ®Acute dosage at 0.6g/kg of bodyweight, split into 2 boluses of 0.4 and 0.2g/kg seperated by 45 mins | Dietary supplement | KetoneIQ® |
| PlaceboTaste, texture, and color matched very low calorie placebo | Dietary supplement | Placebo |
Primary outcome
Cognitive Performance
Time frame: Baseline (minute 0) to Post Suppelementation (minute 45) to Post Exercise (minute 60)
Changes in Score for the Trail Making Test, Psychomotor Vigilance Test, and Flanker Test.
5 secondary outcomes
Changes in Circulating Concentration of Brain Derieved Neurotrophic Factor
Time frame: Baseline (minute 0) to post supplementation (minute 45) to post exercise (minute 60)
Changes in Circulating Catecholamines Concetrations
Time frame: From baseline (minute 0) to post supplemenation (minute 45) to post exercise (minute 60)
Changes in Circulating Cortisol Concentration
Time frame: From baseline (minute 0) to post supplemetation (minute 45) to post exercise (minute 60)
Weapons Familarization Score
Time frame: Post Exercise (minute 60)
Marksmanship efficiency
Time frame: Post Exercise (minute 60)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Nov 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Cognition
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Not yet recruitingPhase 2
Lisdexamfetamine For the Treatment of Conduct Disorder in Children
Conduct Disorder
RecruitingPhase 4
Lidocaine Infiltration and Neuroimmunomodulation in Head and Neck Cancer Surgery
Head and Neck Cancer (H&N)
Recruiting
HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms
Alzheimer Disease, Dementia
RecruitingObservational study
Locus Coeruleus and CCHS (Congenital Central Hypoventilation Syndrome)
Ondine Syndrome (Congenital Central Hypoventilation Syndrome)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Michael J Ormsbee, PhD principal investigator
Florida State University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing KetoneIQ® in people with Cognition, run by Florida State University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Michael J Ormsbee, PhD (850-644-2194, mormsbee@fsu.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cognitive Performance (time frame: Baseline (minute 0) to Post Suppelementation (minute 45) to Post Exercise (minute 60)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Nov 2026.